Skip to content
Search

Latest Stories

US health regulator approves Cipla’s inhalation solution

Shilpa Sharma
By Shilpa SharmaJun 24, 2021
Shilpa Sharma
See Full Bio

PHARMACEUTICAL major Cipla received final consent from the US health regulator for Arformoterol Tartrate inhalation solution.

The approved product is used to treat conditions like chronic bronchitis and emphysema in the US market.

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing on Wednesday (23).

It is a generic version of Sunovion Pharmaceuticals Inc's Brovana.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brovana had sales of around $438 million (£314m) in the US for the 12-month period ending April 2021.

The new product is available for shipping immediately, Cipla said.

ciplaus

Related News

Sanjay Bhandari's extradition appeal opens in London
Business

Sanjay Bhandari's extradition appeal opens in London

Rupert Murdoch looks on as he walks on the day of the hearing on the contentious matter of succession of Rupert Murdoch's global television and publishing empire, in Reno, Nevada, US, September 23, 2024. (Photo: Reuters)
Business

Murdoch's bid to secure eldest son's control of media empire fails

Kamlesh Pattni faces UK sanctions for illicit gold trade
Business

Kamlesh Pattni faces UK sanctions for illicit gold trade

Sanjay Malhotra speaks during the 67th Foundation Day of the Directorate of Revenue Intelligence (DRI) in New Delhi on December 4, 2024. (Photo: Getty Images)
Business

India appoints Sanjay Malhotra as new central bank governor

EasternEye

More For You

Getty Images–Shutterstock deal: what it means for image competition in the UK
Getty Images–Shutterstock deal: what it means for image competition in the UK
iStock

Getty Images–Shutterstock deal: what it means for image competition in the UK

  • £2.9 billion ($3.7 billion) deal faces UK regulatory pressure
  • CMA may require Shutterstock to sell editorial business
  • Concerns centre on reduced competition for UK media outlets

The proposed £2.9 billion ($3.7 billion) merger between Getty Images and Shutterstock is now facing deeper scrutiny in the UK, with regulators signalling that the deal could reshape image competition, particularly in the editorial market.

The Competition and Markets Authority (CMA), which has been reviewing the Getty Images–Shutterstock deal for months, has suggested that Shutterstock may need to sell its entire editorial business for the merger to go ahead. The move reflects growing concern over how much control the combined company could have over images used by UK news organisations.

Keep ReadingShow less